Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Completes Clarient Acquisition

NEW YORK (GenomeWeb) – NeoGenomics announced today it has completed its acquisition of Clarient from GE Healthcare's Life Sciences business.

The deal, which the cancer genetics testing provider first announced in October, has a purchase price of $80 million in cash, $110 million in preferred stock, and 15 million shares of NeoGenomics common stock, the company said in a statement. With the closing of the transaction, GE Healthcare now owns 32 percent of NeoGenomics. The company's board will also expand to include a new director from GE Healthcare, NeoGenomics added.

"We are very pleased to… begin to add Clarient's outstanding capabilities to our strong service offering," said NeoGenomics Chairman and CEO Douglas VanOort in a statement. "Clearly, the acquisition of Clarient is a major step forward in achieving our vision to become America's premier cancer testing laboratory."

Clarient, which is based in California and Texas, has about 415 employees and reported revenue of approximately $127 million in 2014, NeoGenomics said.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.